Genvor Inc (QB) (GNVR)

Genvor Appoints Donald Kalkofen as Chief Financial Officer

Woodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline

Woodland, CA, April 14, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company...

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions

Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™

Woodland, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated...

Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization

Woodland, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated...

Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference

Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...